Table 1.

Patients diagnosed with IDC and undergoing NAC considered in the study. AC = doxorubicin + cyclophosphamide, CarbPac = carboplatin + paclitaxel, Her = trastuzumab, Bev = bevacizumab.

Patient No.	Age	Menopausal status	Lesion size (cm)	Tumor depth (cm)	NAC Response	NAC Treatment
1	57	POST	2.7	NA	pCR	AC-CarbPac+Her
2	45	PRE	1.6	0.72	pCR	AC-CarbPac+Her
3	38	PRE	1.3	NA	pCR	AC-CarbPac
4	56	POST	2.7	0.75	pCR	AC-CarbPac+Her
5	45	POST	1.6	NA	pCR	CarbPac+Bev
6	38	PRE	3	NA	pCR	CarbPac+Her
7	45	PRE	1.3	NA	non-pCR	AC-CarbPac
8	51	POST	6	0.85	non-pCR	AC-CarbPac+Bev
9	33	PRE	2.3	0.99	non-pCR	AC-CarbPac+Bev+Her
10	61	POST	3.3	NA	non-pCR	AC-CarbPac
11	58	POST	1.4	NA	non-pCR	AC
12	55	POST	1.8	NA	non-pCR	AC-CarbPac+Her
13	43	PRE	4	0.67	non-pCR	AC-CarbPac
14	71	POST	3.4	0.36	non-pCR	CarbPac+Her
15	31	PRE	9.8	1.5	non-pCR	CarbPac+Bev